Transdermal testosterone gel: Cellegy

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1629-1632

  McGriff Lee, Nayahmka J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ACNE; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG FORMULATION; DRUG METABOLISM; DRUG SYNTHESIS; EMOTIONAL DISORDER; FEMALE SEXUAL DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GEL; HEADACHE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INJECTION PAIN; NONHUMAN; PERIPHERAL EDEMA; POLYCYTHEMIA; POSTMENOPAUSE; REVIEW; STRUCTURE ACTIVITY RELATION; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ANIMALS; CLINICAL TRIALS; GELS; HUMANS; METHYLTESTOSTERONE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036881422     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 218118 Cellegy awarded US patent for drug delivery system; Technology holds promise for delivery of wide range of drugs through the skin. Cellegy Pharmaceuticals Inc Press Release 1996 September 03
2. 250144 Cellegy Pharmaceuticals utilizes novel anti-inflammatory technology to develop topical testosterone product. Cellegy Pharmaceuticals Inc Press Release 1997 June 13
3. 277560 Cellegy awarded two US patents for drug delivery system; Combination of technologies hold promise for delivery of wider range of drugs through the skin. Cellegy Pharmaceuticals Inc Press Release 1998 February 12
4. 282454 Cellegy awarded multiple foreign patents. Cellegy Pharmaceuticals Inc Press Release 1998 March 27
5. 314726 Cellegy Pharmaceuticals begings clinical trial with its transdermal testosterone gel. Cellegy Pharmaceuticals Inc Press Release 1999 February 11
6. 351823 Cellegy to begin clinical trial with transdermal testosterone gel to treat hormone deficient women. Cellegy Pharmaceuticals Inc Press Release 2000 January 06
7. 361133 Cellegy Pharmaceuticals initiates phase III clinical trial using transdermal testosterone gel. Cellegy Pharmaceuticals Inc Press Release 2000 March 29
8. 382907 Cellegy Pharmaceuticals completes initial clinical trial using Tostrelle in women with sexual dysfunction. Cellegy Pharmaceuticals Inc Press Release 2000 September 20
9. 407000 Cellegy Pharmaceuticals reports first quarter financial results. Cellegy Pharmaceuticals Inc Press Release 2001 April 24
10. 419939 Cellgy Pharmaceuticals and PanGeo Pharma announce supply agreement for Tostrex. Cellegy Pharmaceuticals Inc Press Release 2001 August 21
11. 420610 Cellegy Pharmaceuticals announces positive results from Tostrelle trial. Cellegy Pharmaceuticals Inc Press Release 2001 August 29
12. 428243 Cellegy Pharmaceuticals announces positive results of phase III Tostrex (testosterone gel) trial allowing early completion of study. Cellegy Pharmaceuticals Inc Press Release 2001 November 06
13. 432681 Cellegy issued patent for testosterone gell in the United States. Cellegy Pharmaceuticals Inc Press Release 2001 December 07
14. 437621 Cellegy Pharmaceuticals and Ventiv Health initiate launch planning for Anogesic. Cellegy Pharmaceuticals Inc Press Release 2002 January 25
15. 440942 Cellegy Pharmaceuticals reports 2001 financial results. Cellegy Pharmaceuticals Inc Press Release 2002 February 21
16. 442946 Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: A review of the literature. McGriff NJ, Csako G, Kabbani M, Diep L, Chrousos GP, Pucino F Pharmacotherapy 2001 21 11 1425-1435
17. 442950 Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Snyder PJ, Peachey JH, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL Am J Med 2001 111 4 255-260
18. 442953 Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N Clin Endocrinol 2001 54 6 739-750
19. 442956 Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. Singh AB, Norris K, Modi N, Sinha-Hikim I, Shen R, Davidson T, Bhasin S J Clin Endocrinol Metab 86 6 2437-2445.
20. 442957 Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, Mazer NA J Clin Endocrinol Metab 2001 86 3 1026-1033
21. 442958 Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N J Clin Endocrinol Metab 2000 85 12 4500-4510
22. 442961 Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with testosterone levels. Kenny AM, Prestwood KM, Raisz LG Endocr Res 2000 26 2 153-168
23. 442963 Modeling of circadian testosterone in healthy men and hypogonadal men. Gupta SK, Lindemulder EA, Sathyan G J Clin Pharmacol 2000 40 7 731-738
24. 442966 Polycythaemia as a complication of transdermal testosterone therapy. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL J Haematol 2000 110 1 237-238
25. 442970 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N J Clin Endocrinol Metab 2000 85 8 2839-2853
26. 442973 Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A general clinical research center study. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS, J Clin Endocrinol Metab 2000 85 3 964-969
27. 442978 Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Tan KC, Shiu SW, Kung AW Clin Endocrinol 1999 51 6 765-769
28. 443051 Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: Further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group. Winters SJ, Atkinson L Clin Endocrinol 1997 47 3 317-322
29. 443058 Substitution therapy of hypogonadal men with transdermal testosterone over one year. Bals Pratsch M, Langer K, Place VA, Nieschlag E Acta Endocrinol (Copenh) 1988 118 1 7-13
30. 443059 Transdermal testosterone treatment of hypogonadal men. Carey PO, Howards SS, Vance ML J Urol 1998 140 1 76-79
31. 444857 Cellegy begins phase II/III clinical trial using testosterone gel for the treatment of female sexual dysfunction. Cellegy Pharmaceuticals Inc Press Release 2002 March 26
32. 452161 The therapeutic use of androgens in women. Davis SR Steroid Biochem Mol Biol 1999 69 1-6 177-184
33. 452163 Androgens and sexuality. Hutchinson KA Am J Med 1995 98 1A 111S-115S
34. 452192 Hormones and sexual function. Redmond GP J Fertil Menopausal Stud 1999 44 4 193-197
35. 452202 Androgel. Physician's Desk Reference 2001 3218-3220
36. 452471 Androgens. US Pharma 2000 133-141
37. 453374 Cellegy Pharmaceuticals submits Tostrex new drug application. Cellegy Pharmaceuticals Inc Press Release 2002 June 03
38. 457935 PanGeo Inc. Martin DC Yorkton Securities Inc (Canada) 2002 April 04